<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03176134</url>
  </required_header>
  <id_info>
    <org_study_id>1986-018</org_study_id>
    <secondary_id>2016-003884-20</secondary_id>
    <secondary_id>MK-1986-018</secondary_id>
    <nct_id>NCT03176134</nct_id>
  </id_info>
  <brief_title>A Study of Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Participants From Birth to &lt;12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (MK-1986-018)</brief_title>
  <official_title>A Phase III Randomized, Active-comparator-Controlled Clinical Trial to Study the Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator, in Subjects From Birth to &lt;12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, tolerability, and efficacy of tedizolid phosphate
      (MK-1986) compared with comparator antibacterial agent in participants from birth to &lt;12
      years of age with acute bacterial skin and skin structure infections.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will be randomized (3:1) to receive tedizolid phosphate at a weight-based dose
      ≤200 mg/day, intravenous (IV) and/or oral suspension for 6 to 10 days, or comparator IV
      and/or oral per local standard of care for 10 to 14 days. The switch from IV to oral
      administration can be made at any time based on 1) no worsening of the primary skin lesion,
      2) last temperature &lt;37.7 °C, and 3) primary ABSSSI site has not worsened and at least 1 site
      has improved from Baseline. The potential 4-day treatment extension will be based on clinical
      need as judged by the investigator, considering the following criteria: 1) ≥40% reduction in
      primary lesion size, 2) reduction in pain, and 3) no new signs and symptoms and no
      complications attributable to ABSSSI compared with Baseline.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 20, 2019</start_date>
  <completion_date type="Anticipated">September 18, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 18, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Up to Day 35</time_frame>
    <description>An adverse event (AE) is any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an adverse event. The percentage of participants with one or more AEs will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Study Discontinuations due to an Adverse Event</measure>
    <time_frame>Up to Day 35</time_frame>
    <description>An AE is any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an adverse event. The percentage of participants discontinued from the study due to an AE will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hematopoietic Cytopenias</measure>
    <time_frame>Up to Day 35</time_frame>
    <description>A standardized MedDRA query for hematopoietic cytopenia will be conducted. The percentage of participants with a hematopoietic cytopenia will be reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Success</measure>
    <time_frame>Day 25</time_frame>
    <description>The investigator's assessment of clinical response will be conducted at the Test of Cure (TOC) visit, approximately 25 days after the first infusion. Clinical success is defined as 1) resolution or near-resolution of most signs and symptoms, 2) absence or near-resolution of signs of infection, and 3) no new signs, symptoms, or complications attributable to the infections (no further antibiotic therapy required for the primary lesion). The percentage of participants with clinical success will be reported.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Acute Bacterial Skin and Skin Structure Infections</condition>
  <arm_group>
    <arm_group_label>Tedizolid phosphate: 6 to &lt;12 Years</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive tedizolid phosphate once-daily single 200-mg dose (body weight ≥50 kg) or twice-daily 2-mg/kg doses (body weight 30 kg to &lt;50 kg); or twice-daily 2.5-mg/kg doses (body weight 10 kg to &lt;30 kg), by IV and/or oral suspension for 6 to 10 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator: 6 to &lt;12 Years</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive comparator IV and/or oral per local standard of care for 10 to 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tedizolid phosphate: 2 to &lt;6 Years</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive tedizolid phosphate once-daily single 200-mg dose (body weight ≥50 kg) or twice-daily 2-mg/kg doses (body weight 30 kg to &lt;50 kg); or twice-daily 2.5-mg/kg doses (body weight 10 kg to &lt;30 kg), by IV and/or oral suspension for 6 to 10 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator: 2 to &lt;6 Years</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive comparator IV and/or oral per local standard of care for 10 to 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tedizolid phosphate: 28 Days to &lt;2 Years</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive tedizolid phosphate ≤200 mg daily dose, IV and/or oral suspension for 6 to 10 days. Exact mg/kg dose is to be determined based on results of another study covering the age range.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator: 28 Days to &lt;2 Years</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive comparator IV and/or oral per local standard of care for 10 to 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tedizolid phosphate: Birth to &lt;28 Days Neonates</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive tedizolid phosphate ≤200 mg daily dose, IV and/or oral suspension for 6 to 10 days. Exact mg/kg dose is to be determined based on results of another study covering the age range.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator: Birth to &lt;28 Days (Term and preterm neonates)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive comparator IV and/or oral per local standard of care for 10 to14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tedizolid phosphate</intervention_name>
    <description>Tedizolid phosphate IV solution or oral suspension</description>
    <arm_group_label>Tedizolid phosphate: 2 to &lt;6 Years</arm_group_label>
    <arm_group_label>Tedizolid phosphate: 28 Days to &lt;2 Years</arm_group_label>
    <arm_group_label>Tedizolid phosphate: 6 to &lt;12 Years</arm_group_label>
    <arm_group_label>Tedizolid phosphate: Birth to &lt;28 Days Neonates</arm_group_label>
    <other_name>MK-1986</other_name>
    <other_name>TR-701 FA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator</intervention_name>
    <description>Vancomycin IV, linezolid IV or oral (outside European Union only), clindamycin IV or oral, flucloxacillin IV or oral, cefazolin IV, or cephalexin oral provided locally by the trial site and administered per local standard of care</description>
    <arm_group_label>Comparator: 2 to &lt;6 Years</arm_group_label>
    <arm_group_label>Comparator: 28 Days to &lt;2 Years</arm_group_label>
    <arm_group_label>Comparator: 6 to &lt;12 Years</arm_group_label>
    <arm_group_label>Comparator: Birth to &lt;28 Days (Term and preterm neonates)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ABSSSI, defined as one of the following: 1) cellulitis/erysipelas, 2) major cutaneous
             abscess, 3) wound infection

          -  Local symptoms of ABSSSI that started within 7 days before study start

          -  Suspected or documented Gram-positive bacterial infection

          -  Body weight &gt;5th percentile and &lt;95th percentile based on age.

        Exclusion Criteria:

          -  Uncomplicated skin and skin structure infection

          -  ABSSSI due to or associated with disallowed etiology per protocol

          -  Received antibacterial therapy for treatment of the current episode of ABSSSI except
             1) &lt;24 hours of antibacterial therapy with a short-acting antibacterial drug, or 2)
             response is considered to be failure (no improvement in signs and symptoms) after at
             least 48 hours of therapy

          -  Topical antibacterial applied and remaining on the primary lesion &gt;24 hours before
             randomization

          -  Known bacteremia, severe sepsis, or septic shock

          -  Significant or life-threatening condition, disease, or organ system condition

          -  Recent history of opportunistic infections where the underlying cause of the infection
             is still active, or is suspected to be at risk of opportunistic infection with unusual
             pathogens

          -  Received or is receiving treatment for active tuberculosis within 1 month of study
             start

          -  Known or suspected severe neutropenia

          -  Human immunodeficiency virus (HIV) positive and has Cluster of Differentiation (CD) 4
             cell count &lt;15% (HIV testing is not required for eligibility)

          -  Renal impairment that requires renal filtration

          -  Severe hepatic impairment

          -  Cardiac or electrocardiogram finding that would limit participation in the study

          -  Received an investigational medicinal product (not approved) within 30 days before
             study start

          -  Investigational device present or removed within 30 days before study start

          -  Previously treated with tedizolid phosphate

          -  Contraindication, including hypersensitivity to tedizolid phosphate, other
             oxazolidinones, or any component in the formulation

          -  Contraindication, including hypersensitivity to all available comparator drugs

          -  Wound infection and history of hypersensitivity to aztreonam adjunctive therapy or
             metronidazole adjunctive therapy, if adjunctive therapy is required

          -  Currently receiving topotecan, irinotecan, methotrexate, or rosuvastatin

          -  Female who is pregnant or nursing or is of childbearing potential and not abstinent;
             or male who is not abstinent

          -  Use of monoamine oxidase inhibitors, tricyclic antidepressants, buspirone, selective
             serotonin reuptake inhibitors, or serotonin 5-hydroxytryptamine receptor agonists
             (triptans)

          -  Identified as having used illicit drugs (urine drug screening not required for entry).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rady Children's Hospital-San Diego ( Site 0118)</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>858-966-7785</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago ( Site 0129)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>312-227-6285</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Michigan ( Site 0100)</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>313-745-5863</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital ( Site 0108)</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>248-898-7289</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Louis Children's Hospital ( Site 0127)</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>314-747-5128</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cook Children's Medical Center ( Site 0124)</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>682-885-6740</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine - Texas Children's Hospital ( Site 0107)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>832-824-4336</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Richmond at VCU ( Site 0123)</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hospital Pequeno Principe ( Site 0276)</name>
      <address>
        <city>Curitiba</city>
        <state>Parana</state>
        <zip>80250-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+554133101356</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inst de Medicina Integral Professor Fernando Figueira- IMIP ( Site 0277)</name>
      <address>
        <city>Recife</city>
        <state>Pernambuco</state>
        <zip>50070-550</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+558121224792</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MHAT Sv. Nikolay Chudotvorets EOOD ( Site 0338)</name>
      <address>
        <city>Lom</city>
        <state>Montana</state>
        <zip>3600</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+359971660051</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UMHAT Deva Maria ( Site 0333)</name>
      <address>
        <city>Burgas</city>
        <zip>8127</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+35956896282</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MHAT City Clinic Sv. Georgi EOOD ( Site 0334)</name>
      <address>
        <city>Montana</city>
        <zip>3400</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+359887397013</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MHAT Dr. Stamen Iliev AD ( Site 0339)</name>
      <address>
        <city>Montana</city>
        <zip>3400</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+359887271111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UMHAT Dr. Georgi Stranski EAD ( Site 0330)</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+359886845270</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UMHAT Sv. Georgi ( Site 0332)</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+35932602777</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MBAL Medica Ruse EOOD ( Site 0336)</name>
      <address>
        <city>Ruse</city>
        <zip>7000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+359886353782</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UMHAT Kanev AD ( Site 0337)</name>
      <address>
        <city>Ruse</city>
        <zip>7002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+359888209200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UMHATEM. N.I.Pirogov. EAD ( Site 0331)</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+359888218961</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Haunersches Kinderspital ( Site 0480)</name>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+498951602811</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Civil de Guadalajara Fray Antonio Alcalde ( Site 0230)</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44280</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+523336138233</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Pediatria ( Site 0231)</name>
      <address>
        <city>Mexico City</city>
        <zip>04530</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+525556440210</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Infantil de Mexico Federico Gomez ( Site 0227)</name>
      <address>
        <city>Mexico City</city>
        <zip>06720</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+525552289917x2331</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Obserwacyjno Zakazny ( Site 0429)</name>
      <address>
        <city>Bydgoszcz</city>
        <state>Kujawsko-pomorskie</state>
        <zip>85-030</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48523255605</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Specjalistyczny im. dr. Wladyslawa Bieganskiego ( Site 0427)</name>
      <address>
        <city>Lodz</city>
        <state>Lodzkie</state>
        <zip>91-347</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48422516104</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>City Childrens Clinical Emergency Hospital ( Site 0507)</name>
      <address>
        <city>Novosibirsk</city>
        <state>Novosibirskaya Oblast'</state>
        <zip>630007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79130100310</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emmed Research Incorporating ( Site 0377)</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0084</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27123354767</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Setshaba Research Centre ( Site 0378)</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0152</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27127992422</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Enhancing Care Foundation-DICRS ( Site 0381)</name>
      <address>
        <city>Durban</city>
        <state>Kwazulu-Natal</state>
        <zip>4013</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>27813840820</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cukurova Uni Tip Fak Cocuk Saglıgı ve Hasta ABD ( Site 0353)</name>
      <address>
        <city>Adana</city>
        <zip>01330</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+903223386060</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hacettepe Universitesi Tip Fakultesi Hastanesi ( Site 0351)</name>
      <address>
        <city>Ankara</city>
        <zip>06230</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+903123114963</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Osmangazi UTF ( Site 0357)</name>
      <address>
        <city>Eskisehir</city>
        <zip>26480</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+902222392979</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istanbul Universitesi Istanbul Tip Fakultesi ( Site 0355)</name>
      <address>
        <city>Istanbul</city>
        <zip>34093</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+902124142000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sisli Hamide Etfal Egitim ve Arastirma Hastanesi ( Site 0358)</name>
      <address>
        <city>Istanbul</city>
        <zip>34371</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905055803297</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ege UTF ( Site 0356)</name>
      <address>
        <city>Izmir</city>
        <zip>35040</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+902323901427</phone>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Germany</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 1, 2017</study_first_submitted>
  <study_first_submitted_qc>June 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2017</study_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Skin Diseases, Bacterial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tedizolid</mesh_term>
    <mesh_term>Tedizolid phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

